Sullam P M, Slutkin G, Gottlieb A B, Mills J
Sex Transm Dis. 1986 Jul-Sep;13(3):151-5. doi: 10.1097/00007435-198607000-00007.
A prospective evaluation was made of the therapeutic efficacy of paromomycin, an orally administered, nonabsorbable aminoglycoside, in 114 homosexual men with mild-to-moderate (nondysenteric) intestinal amebiasis. All patients received 25-35 mg/kg daily in three divided doses for seven days. Of the 80 patients with gastrointestinal complaints at the onset of therapy, 55 (80%) of 69 were asymptomatic within four to six weeks after completion of treatment; 11 patients were lost to follow-up. Paromomycin produced long-term eradication of intestinal Entameba histolytica infection in 92% of all men evaluated. The rate of microbiologic cure among patients with symptoms at the onset of therapy was comparable to that among asymptomatic individuals. Paromomycin was well tolerated, with mild diarrhea during therapy the only frequent adverse effect (67% of patients). Thus, paromomycin is an effective alternative to conventional multi-drug therapy for intestinal amebiasis, and it has the advantages of low toxicity, brief duration of therapy, and a high rate of patient compliance.
对114例患有轻至中度（非痢疾性）肠道阿米巴病的同性恋男性患者，进行了口服非吸收性氨基糖苷类药物巴龙霉素治疗效果的前瞻性评估。所有患者每日接受25 - 35mg/kg，分三次给药，共七天。在治疗开始时有胃肠道症状的80例患者中，69例中的55例（80%）在完成治疗后的四至六周内无症状；11例患者失访。在所有接受评估的男性中，92%的患者经巴龙霉素治疗后肠道溶组织内阿米巴感染得到长期根除。治疗开始时有症状的患者中微生物学治愈的比例与无症状个体相当。巴龙霉素耐受性良好，治疗期间仅有轻度腹泻这一常见不良反应（67%的患者）。因此，巴龙霉素是肠道阿米巴病传统多药治疗的有效替代药物，具有低毒性、疗程短和患者依从率高的优点。
